These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Stereotactic Ablative Body Radiotherapy (SABR) in Pulmonary Oligometastatic/Oligorecurrent Non-small Cell Lung Cancer Patients: A New Therapeutic Approach. Agolli L; Valeriani M; Nicosia L; Bracci S; De Sanctis V; Minniti G; Enrici RM; Osti MF Anticancer Res; 2015 Nov; 35(11):6239-45. PubMed ID: 26504057 [TBL] [Abstract][Full Text] [Related]
6. Results of proton beam therapy without concurrent chemotherapy for patients with unresectable stage III non-small cell lung cancer. Oshiro Y; Mizumoto M; Okumura T; Hashimoto T; Fukumitsu N; Ohkawa A; Kanemoto A; Hashii H; Ohno T; Sakae T; Tsuboi K; Sakurai H J Thorac Oncol; 2012 Feb; 7(2):370-5. PubMed ID: 22157368 [TBL] [Abstract][Full Text] [Related]
7. Local control and survival following concomitant chemoradiotherapy in inoperable stage I non-small-cell lung cancer. Campeau MP; Herschtal A; Wheeler G; Mac Manus M; Wirth A; Michael M; Hogg A; Drummond E; Ball D Int J Radiat Oncol Biol Phys; 2009 Aug; 74(5):1371-5. PubMed ID: 19250769 [TBL] [Abstract][Full Text] [Related]
9. Precision Hypofractionated Radiation Therapy in Poor Performing Patients With Non-Small Cell Lung Cancer: Phase 1 Dose Escalation Trial. Westover KD; Loo BW; Gerber DE; Iyengar P; Choy H; Diehn M; Hughes R; Schiller J; Dowell J; Wardak Z; Sher D; Christie A; Xie XJ; Corona I; Sharma A; Wadsworth ME; Timmerman R Int J Radiat Oncol Biol Phys; 2015 Sep; 93(1):72-81. PubMed ID: 26279026 [TBL] [Abstract][Full Text] [Related]
10. Prognostic value of gross tumor volume for definitive radiation therapy in patients with locoregionally recurrent non-small-cell lung cancer after surgical resection. Lee NK; Moon SH; Kim TH; Han JY; Yun T; Kim HT; Lee HS; Kim MS; Lee JM; Cho KH; Lee JS Clin Lung Cancer; 2013 Jul; 14(4):399-406. PubMed ID: 23276823 [TBL] [Abstract][Full Text] [Related]
11. Toxicity and outcome results of a class solution with moderately hypofractionated radiotherapy in inoperable Stage III non-small cell lung cancer using helical tomotherapy. Bral S; Duchateau M; Versmessen H; Engels B; Tournel K; Vinh-Hung V; De Ridder M; Schallier D; Storme G Int J Radiat Oncol Biol Phys; 2010 Aug; 77(5):1352-9. PubMed ID: 20056350 [TBL] [Abstract][Full Text] [Related]
12. Radical treatment of non-small-cell lung cancer patients with synchronous oligometastases: long-term results of a prospective phase II trial (Nct01282450). De Ruysscher D; Wanders R; van Baardwijk A; Dingemans AM; Reymen B; Houben R; Bootsma G; Pitz C; van Eijsden L; Geraedts W; Baumert BG; Lambin P J Thorac Oncol; 2012 Oct; 7(10):1547-55. PubMed ID: 22982655 [TBL] [Abstract][Full Text] [Related]
13. Stereotactic hypofractionated radiotherapy for stage I non-small cell lung cancer--mature results for medically inoperable patients. Nyman J; Johansson KA; Hultén U Lung Cancer; 2006 Jan; 51(1):97-103. PubMed ID: 16213059 [TBL] [Abstract][Full Text] [Related]
14. Ablative dose proton beam therapy for stage I and recurrent non-small cell lung carcinomas : Ablative dose PBT for NSCLC. Lee SU; Moon SH; Cho KH; Pyo HR; Kim JY; Kim DY; Kim TH; Suh YG; Kim YJ Strahlenther Onkol; 2016 Sep; 192(9):649-57. PubMed ID: 27282279 [TBL] [Abstract][Full Text] [Related]
15. Changes of circulating transforming growth factor-beta1 level during radiation therapy are correlated with the prognosis of locally advanced non-small cell lung cancer. Zhao L; Ji W; Zhang L; Ou G; Feng Q; Zhou Z; Lei M; Yang W; Wang L J Thorac Oncol; 2010 Apr; 5(4):521-5. PubMed ID: 20130485 [TBL] [Abstract][Full Text] [Related]
16. Dose-escalation study of three-dimensional conformal thoracic radiotherapy with concurrent S-1 and cisplatin for inoperable stage III non-small-cell lung cancer. Harada H; Nishio M; Murakami H; Ohyanagi F; Kozuka T; Ishikura S; Naito T; Kaira K; Takahashi T; Horiike A; Nishimura T; Yamamoto N Clin Lung Cancer; 2013 Jul; 14(4):440-5. PubMed ID: 23540866 [TBL] [Abstract][Full Text] [Related]
17. Long-term outcome of proton therapy and carbon-ion therapy for large (T2a-T2bN0M0) non-small-cell lung cancer. Iwata H; Demizu Y; Fujii O; Terashima K; Mima M; Niwa Y; Hashimoto N; Akagi T; Sasaki R; Hishikawa Y; Abe M; Shibamoto Y; Murakami M; Fuwa N J Thorac Oncol; 2013 Jun; 8(6):726-35. PubMed ID: 23459403 [TBL] [Abstract][Full Text] [Related]
18. [Survival status of stage IV non-small cell lung cancer patients after radiotherapy--a report of 287 cases]. Cai Y; Wang WL; Xu B; Zhu GY; Zhang SW Ai Zheng; 2006 Nov; 25(11):1419-22. PubMed ID: 17094913 [TBL] [Abstract][Full Text] [Related]
19. Results and prognostic factors of hypofractionated stereotactic radiation therapy for primary or metastatic lung cancer. Kim H; Ahn YC; Park HC; Lim DH; Nam H J Thorac Oncol; 2010 Apr; 5(4):526-32. PubMed ID: 20104193 [TBL] [Abstract][Full Text] [Related]
20. Stereotactic body radiotherapy for centrally located early-stage non-small cell lung cancer or lung metastases from the RSSearch(®) patient registry. Davis JN; Medbery C; Sharma S; Pablo J; Kimsey F; Perry D; Muacevic A; Mahadevan A Radiat Oncol; 2015 May; 10():113. PubMed ID: 25975848 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]